Cytokinetics, Incorporated Cytokinetics, Incorporated

Cytokinetics, Incorporated

CYTK

Peringkat dalam Saham #2254
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Harga Saham
$64.11
Kapitalisasi Pasar
$8.91B
Perubahan (1 hari)
2.34%
Perubahan (1 tahun)
8.03%
Negara
US
Perdagangan Cytokinetics, Incorporated (CYTK)

Kategori

Healthcare
Riwayat pemecahan saham untuk Cytokinetics, Incorporated (CYTK)
Saham Cytokinetics, Incorporated (simbol: CYTK) telah mengalami total 1 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Jun 25, 2013.
Satu lembar saham CYTK yang dibeli sebelum Jun 25, 2013 sekarang setara dengan 0.16666666666667 lembar saham CYTK.
Daftar pemecahan saham
Tahun Pemecahan Kelipatan Kelipatan Kumulatif
2013-06-25 1:6 x0.16666666666667 x0.16666666666667
Pemecahan saham untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pemecahan saham Kelipatan Kumulatif Negara
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL